Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia Academic Article


  • Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p

publication date

  • 2007/10/1


  • Anti-Idiotypic Antibodies
  • Colombia
  • Cross-Sectional Studies
  • Enzyme-Linked Immunosorbent Assay
  • Genes
  • Health
  • Hepatitis B Vaccines
  • Synthetic Vaccines
  • Vaccination

International Standard Serial Number (ISSN)

  • 0120-8322

number of pages

  • 7

start page

  • 375

end page

  • 381